WG Biotech ApS - 11 Dec 2023 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Director
Signature
WG Biotech ApS by /s/ Johan Wedell-Wedellsborg
Issuer symbol
YMAB
Transactions as of
11 Dec 2023
Net transactions value
+$44,232
Form type
4
Filing time
12 Dec 2023, 08:27:16 UTC
Previous filing
11 Dec 2023
Next filing
18 Sep 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common stock Purchase $44,232 +6,455 +0.14% $6.85 4,559,233 11 Dec 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades each at price of $6.85 to 6.86. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

Johan Wedell-Wedellsborg is the majority owner of WG Biotech ApS and has sole voting and dispositive power over the shares of the Issuer held by WG Biotech ApS. Mr. Wedell-Wedellsborg serves as a director of the Issuer. In connection therewith, WG Biotech ApS may be deemed to be a director by deputization of the Issuer solely for purposes of Section 16(a) of the Exchange Act. As a result, WG Biotech ApS is listed as a "Reporting Person" in Item 1 and the "Director" box is marked in Item 5 of this Form 4. This filing shall not be deemed an admission by Reporting Person on this Form 4 that such person is a director of the Issuer by deputization.